Lucas Villas Bôas Hoelz

Lucas Villas Bôas Hoelz

Auto-generated profile, based on publicly available information

Lucas Villas Bôas Hoelz

Fundação Oswaldo Cruz

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Letters in Applied Microbiology
Verified
Journal Article
Open access
PDF file
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
LHLucas V.B. Hoelz
Lucas V.B. Hoelz
MFMaria de Lourdes G. Ferreira
Maria de Lourdes G. Ferreira
LOLarissa G. Oliveira
Larissa G. Oliveira
RENATA PEREIRARENATA PEREIRA
RENATA PEREIRA
Fabio Aguiar-AlvesFabio Aguiar-Alves
Fabio Aguiar-Alves
Following the appearance of several antimicrobial agents to control the spread of infections, two major challenges have emerged: 1‐ the occurrence and blowout of multiresistant bacteria and the increase of chronic diseases, and 2‐ difficult‐to‐eradicate infections. In this study, we tested five benzoylthiourea derivatives for their ability to inhibit and stop bacterial growth and evaluated the possible influence of 1,2,4‐triazolyl‐benzoylthiourea derivative 4 on the formation and eradication of S. aureus biofilms. Benzoylthiourea derivatives 4 , 6 , 10 , 11, and 13 were obtained in one or two steps with low cost and subjected to tests to identify their minimum inhibitory concentration and minimum bactericidal concentration. In vitro tests were also performed to assess their effects on biofilm formation and in preformed biofilms and scanning electron microscopy was used to visualize the effects on biofilm formation. The 1,2,4‐triazolyl‐benzoylthiourea derivative 4 showed bacteriostatic activity against the Staphylococcus aureus HU25 clinical strain with an minimum inhibitory concentration (MIC) of 16 µg.mL‐1, which is below the toxic concentration (at 2,500 µg.mL‐1, 62.25% of the cells remained viable). Compound 4 also effectively prevented biofilm formation at the three subinhibitory concentrations tested (1/2 MIC, 1/4 MIC and 1/8 MIC) as confirmed by SEM. For breakdown of formed biofilms, the main influence was at a subinhibitory concentration (1/2 MIC). These findings make compound 4 a strong candidate for studies on the development of new antimicrobial and antibiofilm agents.

18 March 2020 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
LPLuiz Claudio Ferreira Pimentel
Luiz Claudio Ferreira Pimentel
ACAnna Claudia Cunha
Anna Claudia Cunha
LHLucas Villas Boas Hoelz
Lucas Villas Boas Hoelz
HCHenayle Fernandes Canzian
Henayle Fernandes Canzian
DMDebora Inacio Leite Firmino Marinho
Debora Inacio Leite Firmino Marinho
MBMonica Macedo Bastos
Monica Macedo Bastos
The phenylamino-pyrimidine (PAP) nucleus has been demonstrated to be useful for the development of new drugs and is present in a wide variety of antiretroviral agents and tyrosine kinase inhibitors (TKIs). This review aims to evaluate the application of PAP derivatives in drugs and other bioactive compounds. It was concluded that PAP derivatives are still worth exploring, as they may provide highly competitive ATP TKI’s with nano/picomolar activity.

1 September 2021 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RFRodolfo Rodrigo Florido França
Rodolfo Rodrigo Florido França
CMCheyene Almeida Celestino Menozzi
Cheyene Almeida Celestino Menozzi
FBFrederico Silva Castelo Branco
Frederico Silva Castelo Branco
LHLucas Villas Bôas Hoelz
Lucas Villas Bôas Hoelz
NBNubia Boechat
Nubia Boechat
: Infectious diseases are among the leading causes of death worldwide, especially in developing countries. The historical lack of interest of the pharmaceutical industry in developing new drugs against many of these diseases, such as tuberculosis, leishmaniasis, Chagas disease, sleeping sickness, and fungal infections, has left millions of individuals dependent on old treatments that are often ineffective and present different adverse effects. In this sense, new substances against these diseases must be identified. A class of substances that has stood out in the search for new drugs against these diseases is azole derivatives. Within this class, the 3-nitro-1,2,4-triazole nucleus has attracted increasing interest due to its potential, specifically when compared to the 1,2,4-triazole nucleus without the presence of the nitro group, and also in relation to the 2-nitroimidazole nucleus, showing greater potency and selectivity against different etiological agents. This is even more relevant considering that 3-nitro-1,2,4-triazolic substances can promote their activity through different mechanisms of action, such as the inhibition of ergosterol biosynthesis and also via activation by the nitroreductase enzyme, which can avoid the development of cross-resistance. Therefore, in this review, the medicinal chemistry of nitrotriazoles is discussed through the analysis of their potential in terms of biological activity against the etiological agents of several diseases, such as Chagas disease, sleeping sickness and leishmaniasis, caused by kinetoplastid parasites, tuberculosis, caused by the mycobacteria Mycobacterium tuberculosis, and against different species of pathogenic fungi. In addition, aspects related to enzymatic activities, molecular modeling and organic synthesis of these substances are also addressed.

24 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Carolina SacramentoCarolina Sacramento
Carolina Sacramento
GMGabrielle R. de Melo
Gabrielle R. de Melo
Caroline De FreitasCaroline De Freitas
Caroline De Freitas
NRNatasha Rocha
Natasha Rocha
LHLucas Villas Bôas Hoelz
Lucas Villas Bôas Hoelz
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
Scientific Reports 7: Article number: 40920; published online 18 January 2017; updated on 24 April 2017 The Competing Financial Interests section in this Article is incorrect and should read: “Dr. Karin Brüning is a member of the BMK consortium, able to produce sofosbuvir”.

10 August 2010 in Australian Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
LHLucas V. B. Hoelz
Lucas V. B. Hoelz
This paper provides a description of tribromoisocyanuric acid (TBCA), a new reagent used as a source of electrophilic bromine (Br+) in organic synthesis, including in Green Chemistry procedures. Its applications embrace the bromination of alkenes, ß-dicarbonyl compounds and deactivated arenes, as well as oxidations of urazoles, bisurazoles, and thiols.

27 April 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
CRCaroline Rodrigues Chaves dos Reis
Caroline Rodrigues Chaves dos Reis
HSHellen Valério Chaves Moura de Souza
Hellen Valério Chaves Moura de Souza
RLRennan Papaleo Paes Leme
Rennan Papaleo Paes Leme
FBFrederico Silva Castelo Branco
Frederico Silva Castelo Branco
TFTACIO VINICIO AMORIM FERNANDES
TACIO VINICIO AMORIM FERNANDES
LHLucas Villas Bôas Hoelz
Lucas Villas Bôas Hoelz
There are only two drugs for the treatment of Chagas disease, namely, nifurtimox and benznidazole, that can cause several adverse effects. Despite the effectiveness of these drugs in the disease's acute phase, they are not recognized as curative in the chronic phase, establishing the need for more effective treatment in all stages of the disease. Cruzain is an enzyme that plays a vital role in the life cycle of the etiologic agent, the protozoan Trypanosoma cruzi, being relevant as a therapeutic target in the planning of new drugs. Using molecular docking and dynamics simulations, we have investigated the structural and dynamic factors that can be involved in the enzyme inhibition process at the atomic-molecular level by benzimidazole compounds that are potent cruzain inhibitors with in vitro trypanocidal activity. The study suggests that these inhibitors bind cruzain through steric and hydrogen bonding interactions without altering its secondary structure content and protein compaction. Besides, we observed that these inhibitors decrease the correlation of movements between Cα-atoms of cruzain, increasing the number of atomic communities, mainly in the α-helix that presents the catalytic Cys25 residue. As expected, we also observed a correlation between the inhibitory activity of each inhibitor and their respective binding-free energies, reinforcing that the affinity of the complexes seems to be a relevant factor for enzymatic inhibition. Hence, the results presented in this work contribute to a better understanding of the cruzain enzyme inhibition mechanism through competitive and non-covalent inhibitors. Communicated by Ramaswamy H. Sarma